ATE485377T1 - Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen - Google Patents

Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen

Info

Publication number
ATE485377T1
ATE485377T1 AT02706572T AT02706572T ATE485377T1 AT E485377 T1 ATE485377 T1 AT E485377T1 AT 02706572 T AT02706572 T AT 02706572T AT 02706572 T AT02706572 T AT 02706572T AT E485377 T1 ATE485377 T1 AT E485377T1
Authority
AT
Austria
Prior art keywords
methods
manf
survival
dopaminergic neurons
substantially purified
Prior art date
Application number
AT02706572T
Other languages
English (en)
Inventor
John Commissiong
Andrei Raibekas
Original Assignee
Cns Protein Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23061211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE485377(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cns Protein Therapeutics Inc filed Critical Cns Protein Therapeutics Inc
Application granted granted Critical
Publication of ATE485377T1 publication Critical patent/ATE485377T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02706572T 2001-03-20 2002-03-20 Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen ATE485377T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27751601P 2001-03-20 2001-03-20
PCT/CA2002/000373 WO2002074956A2 (en) 2001-03-20 2002-03-20 Dopaminergic neuronal survival-promoting factors and uses thereof

Publications (1)

Publication Number Publication Date
ATE485377T1 true ATE485377T1 (de) 2010-11-15

Family

ID=23061211

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02706572T ATE485377T1 (de) 2001-03-20 2002-03-20 Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen

Country Status (9)

Country Link
US (5) US20020182198A1 (de)
EP (1) EP1373502B8 (de)
JP (1) JP2004528835A (de)
AT (1) ATE485377T1 (de)
CA (1) CA2441740A1 (de)
DE (1) DE60238038D1 (de)
DK (1) DK1373502T3 (de)
ES (1) ES2353490T3 (de)
WO (1) WO2002074956A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238038D1 (de) 2001-03-20 2010-12-02 Cns Protein Therapeutics Inc Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
US7452969B2 (en) * 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
EP1644406B1 (de) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Verwendung von dg153 sekretierter proteinprodukte zur prevention und behandlung von pankreaserkrankungen und/oder fettleibigkeit und/oder metabolischem syndrom
PL1969003T3 (pl) * 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
WO2009120810A2 (en) * 2008-03-25 2009-10-01 Cns Protein Therapeutics, Inc. Neurodegenerative disorders
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2011038366A1 (en) * 2009-09-25 2011-03-31 Amarantus Therapeutics, Inc. Dopaminergic selective factors
CA2838818A1 (en) * 2011-06-09 2012-12-13 University Of Miami Methods of treatment for retinal diseases
FI20115870A0 (fi) * 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
EP2820424B1 (de) * 2012-01-24 2016-12-07 University of Massachusetts Löslicher manf in pankreas-betazellen-erkrankungen
EP3122370A1 (de) * 2014-03-28 2017-02-01 Buck Institute for Research on Aging Verfahren und zusammensetzungen zur modulierung der immunreaktion
US20190192629A1 (en) * 2015-11-18 2019-06-27 Herantis Pharma Plc Compositions Comprising CDNF or MANF for use in the Intranasal Treatment of Central Nervous System Diseases
EP3774858B1 (de) * 2018-03-29 2025-07-30 MyNeuroCure Oy C-terminale cdnf-fragmente mit neuroprotektiver wirkung
CN113292656B (zh) * 2020-02-21 2022-10-25 四川大学华西医院 用于防治肥胖的中脑星形胶质细胞源性神经营养因子的融合蛋白

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019851A2 (en) * 1999-09-16 2001-03-22 Neurotrophic Bioscience Inc. Opaminergic neuronal survival-promoting factors and uses thereof
EP1225224A4 (de) * 1999-10-01 2004-03-24 Kyowa Hakko Kogyo Kk Dna der scherbelastungsantwort
AU2001250912B2 (en) * 2000-03-21 2007-01-04 Curagen Corporation VEGF-modulated genes and methods employing them
DE60238038D1 (de) 2001-03-20 2010-12-02 Cns Protein Therapeutics Inc Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
EP1373314A2 (de) * 2001-03-30 2004-01-02 Geneprot, Inc. Menschliches arginin-reich protein ähnliche zusammensetzungen
WO2002090541A1 (en) * 2001-05-03 2002-11-14 Murdoch Childrens Research Institute Determination of a genetic predisposition for behavioural disorders
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
US7452969B2 (en) 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof
US20060195915A1 (en) 2002-08-30 2006-08-31 Licentia Ltd. Novel neurotrophic factor protein and uses thereof
WO2009120810A2 (en) 2008-03-25 2009-10-01 Cns Protein Therapeutics, Inc. Neurodegenerative disorders
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
CA2838818A1 (en) 2011-06-09 2012-12-13 University Of Miami Methods of treatment for retinal diseases

Also Published As

Publication number Publication date
US20100119491A1 (en) 2010-05-13
US9115208B2 (en) 2015-08-25
EP1373502B1 (de) 2010-10-20
US20020182198A1 (en) 2002-12-05
ES2353490T3 (es) 2011-03-02
WO2002074956A3 (en) 2003-07-10
CA2441740A1 (en) 2002-09-26
US8084425B2 (en) 2011-12-27
US20170298110A1 (en) 2017-10-19
EP1373502A2 (de) 2004-01-02
EP1373502B8 (de) 2010-12-22
DE60238038D1 (de) 2010-12-02
JP2004528835A (ja) 2004-09-24
DK1373502T3 (da) 2011-01-10
US20130078220A1 (en) 2013-03-28
WO2002074956A2 (en) 2002-09-26
US20160152673A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
DE60238038D1 (de) Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
DE60238999D1 (de) Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
ATE370225T1 (de) Differenzierung von knochenmarkzellen in neuronale zellen und deren verwendungen
ES2188793T3 (es) Agente para el tratamiento de las enfermedades neurodegenerativas.
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
CY1106898T1 (el) Χρηση d-σερινης ή d-αλανινης για την αντιμετωπιση της σχιζοφρενειας
ATE490786T1 (de) Behandlung von verletzungen des zentralen nervensystems
BR0015533A (pt) Iduronidase-alfa-l recombinante, métodos para sua produção e purificação e métodos para tratamento de doenças causadas por deficiências da mesma
PT751939E (pt) Naftilamidas como agentes para o sistema nervoso central
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
ATE382366T1 (de) Modifizierte myelin proteinmoleküle
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
EP1351968A4 (de) "alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus "
ATE311476T1 (de) Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
BR9814945A (pt) Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
WO2001019851A3 (en) Opaminergic neuronal survival-promoting factors and uses thereof
ATE348158T1 (de) Neuartiges collectin
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
DE60004093D1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties